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We investigated the impact of the piperacillin-tazobactamMIC in the outcome of 39 bloodstream infections due to extended-
spectrum--lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC.
For other sources, 30-day mortality was lower for isolates with aMIC of<2 mg/liter than for isolates with a higher MIC (0% ver-
sus 41.1%; P 0.02).
Carbapenems are considered the drugs of choice for treatingsevere infections caused by extended-spectrum--lactamase
(ESBL)-producing Enterobacteriaceae (1). There is an increasing
interest in investigating potential alternatives to these drugs be-
cause of the spread of carbapenemase-producing organisms. Re-
cently, in a post hoc analysis of prospective cohorts, we showed that
-lactam/-lactam inhibitor combinations (BLBLI), including
amoxicillin-clavulanate and piperacillin-tazobactam (PTZ),
showed efficacy similar to that of carbapenems in treating blood-
stream infections (BSI) due to susceptible ESBL-producing Esch-
erichia coli (ESBLEC) (2). The objective of this study was to ana-
lyze the impact of the MICs of PTZ, and of other variables, on the
outcome of patients with BSI due to ESBLEC, treated empirically
with this antibiotic.
Cases included in this analysis were selected from a merged
database of 6 previously reported prospective cohorts of adult
(17-year-old) patients with BSI due to ESBLEC; the character-
istics of the cohorts and an analysis comparing patients treated
with BLBLI and carbapenems when active in vitro have been pre-
viously reported (2). Here, all patients from those cohorts treated
with PTZ, irrespective of the MIC of the isolate, were included
(resistant isolates were excluded from the previous report [2]),
provided that (i) bacteremia was monomicrobial, along with cri-
teria for sepsis, (ii) the patients received empirical monotherapy
with PTZ, and (iii) the first PTZ dose was administered intrave-
nously within the first 24 h after the blood culture was drawn. The
study was approved by the Ethics Committee of the Hospital Uni-
versitario Virgen Macarena, Sevilla, Spain. The microbiological
studies carried out have been published previously (2). Suscepti-
bility testing was performed by microdilution. Isolates showing a
PTZMIC of8mg/liter were considered susceptible according to
EUCAST (3); also, for the purpose of this analysis, the isolates
were classified as showing “highMIC” (nonsusceptible isolates or
aMICof16mg/liter), “intermediateMIC” (4 to 8mg/liter), and
“lowMIC” (2mg/liter) (Fig. 1). Themain outcome variable was
all-cause 30-day mortality. More than 90% of the patients re-
ceived 4,500 mg of PTZ intravenously every 6 h. Comparisons of
percentages were performed by Fisher’s exact test (2-tailed).
Thirty-nine patients with bacteremia due to ESBLEC received
empirical monotherapy with PTZ and were included. Eighteen
isolates (46.1%) showed a low MIC (2 mg/liter), 10 (25.6%)
showed an intermediate MIC (4 to 8 mg/liter), and 11 (28.2%)
showed a highMIC (8mg/liter). All-cause 30-daymortality was
17.9% (7 patients). The features of the patients according to the
MIC are shown in Table S1 in the supplemental material; while
there were not statistically significant differences among the 3
groups in demographic features, nosocomial acquisition, severity
of underlying disease according to the Charlson index, source, or
presentation with severe sepsis/septic shock, it should be noted
that numbers were low and that patients infected with high-MIC
isolates somehow showed more frequently a Charlson index
of2.
Mortality according to exposure to various characteristics of
the patients is shown in Table 1 and Fig. 1. When all patients were
considered, irrespective of theMIC, only presentation with severe
sepsis or shockwas associatedwith increasedmortality. Regarding
theMIC subsets, no patientwith a low-MIC isolate died.Mortality
was lower among patients with a low-MIC isolate than those with
a high-MIC isolate.Mortalitywas also significantly higher for high
MICs than for low and intermediate MICs combined (57.1% ver-
sus 57.1%; relative risk [RR] 0.21; 95%confidence interval [CI],
0.06 to 0.75; P 0.01) and for intermediate and high MICs com-
bined than for low MICs (41.1% versus 0%; RR 0.13; 95% CI,
0.01 to 0.98; P  0.002). None of the 11 patients with a urinary
tract source died, irrespective of MIC. Among patients with non-
urinary tract sources, mortality was lower among patients with
low-MIC isolates. The features of the patients who died are shown
in Table S2 in the supplemental material.
The availability of amerged database that included prospective
cohorts of patients with BSI infections due to ESBLEC who had
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been carefully followed provided us with the opportunity to in-
vestigate the influence of the MIC and other variables on the out-
come of patients who received empirical treatment with PTZ. Our
results show that themortality of patients treated empirically with
high doses of PTZ correlated with MIC values and that those pa-
tients with a low MIC (2 mg/liter) had significantly lower mor-
tality. We chose this particular breakpoint because it is the mode
MIC for wild-type E. coli and 85% of wild-type isolates had MICs
of2 mg/liter (4).
These data, however, should be interpreted alongside other
variables that influence mortality in patients with BSI, such as
source of infection or severity of systemic inflammatory response
syndrome (SIRS) at presentation (5). Since collecting a high num-
ber of cases with different MICs treated with a specific antimicro-
bial is difficult, controlling for confounders is challenging. Multi-
variate analysis was not possible due to low numbers, so we
performed a stratified analysis in order to give some insight into
the impact of these variables on MIC categories. From this analy-
sis, a few data may be mentioned. First, there was no mortality
among patients with urinary tract infections treated with PTZ,
irrespective of the MIC. Second, mortality was higher in patients
with intermediate and high MICs of PTZ against BSI from other
sources. Finally, stratification by severity of SIRS at presentation
(or any other variable) did not seem to strongly modify the rela-
tionship between MIC and mortality.
Wepreviously showed that empirical or definitive therapywith
active BLBLI (including PTZ and amoxicillin-clavulanate)
showed mortality and hospital stay similar to those of carbapen-
ems in patients with BSI due to susceptible ESBLEC (3). In that
study, we stated that the results were applicable mainly to patients
with bacteremia from the urinary tract because that was the dom-
inant source. In addition, Gavin et al. found that PTZ cured 13
patients with urinary tract infections, irrespective of MIC, al-
though they did not specify whether or not the infections were
bacteremic (6). This is probably due to the high concentrations
reached by these antibiotics in the urine and to the fact that uri-
nary tract bacteremic infections are associated with lower mortal-
ity rates (5).However, we donot advocate empiricalmonotherapy
with PTZ for patients with urinary tract sepsis in any context of
moderate to high resistance to these antibiotics.
Our results also suggest that PTZ may be safely used in bacte-
remia from some non-urinary tract sources, at least if the MIC is
low enough (2 mg/liter); most of the patients in this category
had intra-abdominal infections, so this may apply only to this
particular source, in which appropriate surgical therapy is fre-
quently key. More studies are required for isolates with MICs
between 4 and 8 mg/liter because the few patients with such
isolates had mortality rates similar to those with resistant iso-
lates. This contrasts with the results of Gavin et al., who found
that 8 patients with non-urinary tract infections (sites and in-
vasive condition not specified) caused by ESBL-producing E.
coli or Klebsiella spp. and showing MIC values of 4 or 8 mg/liter
were cured with this antimicrobial (6). It is noted that the CLSI
PTZ breakpoint for susceptibility against Enterobacteriaceae is
16 mg/liter (7) while the EUCAST breakpoint is8 mg/liter
(3), according to data from some pharmacokinetic-pharmaco-
dynamic models (8).
Our study has several limitations. The statistical power of the
study was limited because of the low numbers involved and was
also insufficient to carry outmore-suitable analyses for identifying
PTZMIC values that are predictive of treatment outcome, such as
a classification and regression tree (CART) analysis or a multivar-
iate analysis with different breakpoints. The data may not be ap-
plicable to enterobacteria other than E. coli. Finally, the effect of
other aspects of management or confounders was not able to be
studied.
In summary, our results suggest that PTZ is effective for treat-
ing urinary tract bacteremia caused by ESBLEC. For other sources,
FIG 1 Mortality of patients with bacteremia due to ESBL-producing Escherichia coli treated empirically with piperacillin-tazobactam, according to source and
MIC. aOne had severe sepsis/shock (survived). bOne had severe sepsis/shock (survived). cTwo had severe sepsis/shock (one died). dThree had severe sepsis/shock
(two died).
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particularly intra-abdominal infections, PTZ showed better re-
sults against isolates showing a low MIC.
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TABLE 1Mortality among patients with bacteremia due to ESBL-
producing E. coli who were treated empirically with piperacillin-
tazobactam, according to MIC and other variables of interest
Variable and group
Mortality in patients in each groupa
All patients
(n 39)
Low MIC
(2 mg/liter)
(n 18)
Intermediate
MIC (4 to 8
mg/liter)
(n 10)
High MIC
(16 mg/liter)
(n 11)
All patients 7/39 (17.9) 0/18 (0)b 3/10 (30) 4/7 (57.1)
Age
65 years 4/20 (20) 0/9 (0) 1/5 (20) 3/6 (50)
65 years 3/19 (15.8) 0/9 (0) 2/5 (40) 1/5 (20)
Onset
Community 2/21 (9.5) 0/10 (0) 1/5 (20) 1/6 (16.7)
Nosocomial 5/18 (27.8) 0/8 (0) 2/5 (40) 3/5 (60)
Charlson index
2 4/24 (16.7) 0/12 (0) 3/8 (37.5) 1/4 (25)
2 3/15 (20) 0/6 (0) 0/2 (0) 3/7 (42.9)
Source
Urinary tract 0/11 (0) 0/7 (0) 0/2 (0) 0/2 (0)
Other 7/28 (25) 0/11 (0)c 3/8 (37.5) 4/9 (44.4)
Severe sepsis or shock
No 4/32 (12.5)d 0/16 (0) 2/8 (25) 2/8 (25)
Yes 3/7 (42.8) 0/2 (0) 1/2 (50) 2/3 (66.7)
Definitive therapye
PTZ 0/10 0/5 (0) 0/4 (0) 0/1 (0)
Carbapenem 5/24 (20.8) 0/10 (0) 1/4 (25) 4/10 (40)
Other 0/3 (0) 0/3 (0)
a Data are expressed as number of patients who died/number of patients in each
category (percentage). PTZ, piperacillin-tazobactam.
b Low MIC versus intermediate MIC, P 0.08; low MIC versus high MIC, P 0.005.
P values were obtained by Fisher’s test; only those0.1 are shown.
c Low MIC versus intermediate MIC, P 0.05; low MIC versus high MIC, P 0.02.
P values were obtained by Fisher’s test; only those0.1 are shown.
d Presentation without versus with severe sepsis or shock, P 0.09. P values were
obtained by Fisher’s test; only those0.1 are shown.
e Only patients who survived long enough to receive definitive therapy were included.
Other sources included biliary tract (6), unknown and spontaneous peritonitis (2 each),
and secondary peritonitis (1) for low MIC, biliary tract (4) and respiratory tract, skin
and skin structure, catheter, and unknown (1 each) for intermediate MIC, and biliary
tract (3), spontaneous peritonitis and skin and skin structure (2 each), and respiratory
tract and secondary peritonitis (1 each) for high MIC.
Retamar et al.
3404 aac.asm.org Antimicrobial Agents and Chemotherapy
